Literature DB >> 34318097

Commentary: Trifecta valve: Does a word of caution prevail?

Ko Bando1.   

Abstract

Entities:  

Year:  2020        PMID: 34318097      PMCID: PMC8300029          DOI: 10.1016/j.xjtc.2020.11.010

Source DB:  PubMed          Journal:  JTCVS Tech        ISSN: 2666-2507


× No keyword cloud information.
Ko Bando, MD, PhD Although Trifecta valves provided excellent hemodynamics, unpredictable structural valve deterioration associated with abrupt leaflet tear remains a major concern. See Article page 106 in the December 2020 issue. The use of bioprosthetic valves for surgical aortic valve replacement has increased during the last few decades due to continuous improvements in durability and hemodynamic performance., Many commercially available aortic bioprosthetic valves have been modified to increase their effective orifice area, minimize transvalvular pressure gradient, and avoid patient–prosthetic mismatch (PPM) after surgery. The Trifecta bioprosthetic aortic valve (Abbott, St Paul, Minn) is a trileaflet, stented pericardial valve designed for supra-annular placement during surgical aortic valve replacement. The valve leaflets are made from a single bovine pericardial tissue that is externally mounted on a titanium stent to maximize hemodynamic performance., The Trifecta valve has shown excellent hemodynamic performance with a low transvalvular gradient, acceptable effective orifice area, and low rates of PPM. However, a number of early Trifecta valve failures have been reported, and the most common cause of dysfunction was aortic regurgitation due to leaflet tear involving the noncoronary cusp and pannus formation in the inflow portion.6, 7, 8, 9, 10 Although the mechanism of these early failures is unclear, it has been suggested that technical failures, such as incautious knot tying, oversized valve selection, and accidental bending of the sewing ring or the titanium stent posts, may cause a change in valve geometry, eventually leading to leaflet damage and tearing. To avoid these technical pitfalls, the next-generation Trifecta valve with Glide Technology (Trifecta GT; Abbott) was introduced in 2016. This new valve allows easier suturing and better placement in the native annulus, with a modified holder to facilitate parachuting and seating to minimize distortion to the stent and leaflets. Thocuta and colleagues reported an unexpected early failure of the refined Trifecta GT that presented as newly diagnosed severe aortic insufficiency associated with a detached cusp at the stent post between the noncoronary and the right coronary cusps. Noncalcified leaflet tears at the stent post or at the bottom of the leaflet without significant leaflet calcification are rather typical for Trifecta valves, whereas slow progress of calcification has been the primary cause of structural valve deterioration (SVD) in other types of bioprosthetic valves. Given the characteristics and timing of the SVD in the newer Trifecta GT, hemodynamic or mechanical stress on the externally mounted leaflet of the valve may contribute to the incidence of SVD, as has been seen among other externally mounted leaflet valves, including the Ionescu–Shiley valves in the 1980s,, and the recent-generation Mitroflow valves in the 2000s. Trifecta valves provided excellent early- to mid-term hemodynamic performance and a very low rate of PPM up to 6 or 7 years after surgery.,, The absolute number of observed SVD cases remains limited., However, clinical presentation of SVD caused by abrupt valve tears often involves sudden-onset severe dyspnea and heart failure and may require emergent redo surgery or a valve-in-valve procedure.,, Physicians involved in the follow-up of these patients should always keep in mind the possibility of rapid SVD in the Trifecta valve. Thus, I recommend a “word of caution” regarding this valve.
  17 in total

1.  Early Trifecta valve failure: Report of a cluster of cases from a tertiary care referral center.

Authors:  Ankur Kalra; Hasan Rehman; Mahesh Ramchandani; Colin M Barker; Gerald M Lawrie; Ross M Reul; Michael J Reardon; Neal S Kleiman
Journal:  J Thorac Cardiovasc Surg       Date:  2017-05-22       Impact factor: 5.209

2.  St Jude Medical Trifecta aortic prosthesis: Considerations for implantation.

Authors:  W R Eric Jamieson
Journal:  J Thorac Cardiovasc Surg       Date:  2015-03-28       Impact factor: 5.209

3.  Early failures of Trifecta aortic bioprosthesis.

Authors:  Salvatore Campisi; Lionel Camilleri; Andrea Innorta; Kasra Azarnoush
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-20       Impact factor: 5.209

4.  Ionescu-Shiley valve failure. II: Experience with 25 low-profile explants.

Authors:  V M Walley; C A Keon; M Khalili; D Moher; M Campagna; W J Keon
Journal:  Ann Thorac Surg       Date:  1992-07       Impact factor: 4.330

5.  Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients.

Authors:  Thomas Sénage; Thierry Le Tourneau; Yohann Foucher; Sabine Pattier; Caroline Cueff; Magali Michel; Jean-Michel Serfaty; Antoine Mugniot; Christian Périgaud; Hubert François Carton; Ousama Al Habash; Olivier Baron; Jean Christian Roussel
Journal:  Circulation       Date:  2014-10-29       Impact factor: 29.690

Review 6.  Early hemodynamic performance of the third generation St Jude Trifecta aortic prosthesis: A systematic review and meta-analysis.

Authors:  Kevin Phan; Hakeem Ha; Steven Phan; Martin Misfeld; Marco Di Eusanio; Tristan D Yan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-07       Impact factor: 5.209

7.  Trifecta versus Perimount Magna Ease Aortic Valve Prostheses.

Authors:  Fausto Biancari; Antti Valtola; Tatu Juvonen; Annastiina Husso; Sebastian Dahlbacka; Teemu Laakso; Maina P Jalava; Tuomas Tauriainen; Tuomas Ahvenvaara; Eeva-Maija Kinnunen; Matti Niemelä; Timo Mäkikallio; Markku Eskola; Marko P O Virtanen; Pasi Maaranen; Stefano Rosato; Vesa Anttila; Antti Vento; Juhani Airaksinen; Peter Raivio
Journal:  Ann Thorac Surg       Date:  2020-02-12       Impact factor: 4.330

8.  Mid-term durability of the Trifecta bioprosthesis for aortic valve replacement.

Authors:  Amedeo Anselmi; Vito Giovanni Ruggieri; Bernard Lelong; Erwan Flecher; Hervé Corbineau; Thierry Langanay; Jean-Philippe Verhoye; Alain Leguerrier
Journal:  J Thorac Cardiovasc Surg       Date:  2016-08-30       Impact factor: 5.209

9.  The St Jude Medical Trifecta aortic pericardial valve: results from a global, multicenter, prospective clinical study.

Authors:  Joseph E Bavaria; Nimesh D Desai; Anson Cheung; Michael R Petracek; Mark A Groh; Michael A Borger; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03-07       Impact factor: 5.209

10.  Early failure of the Trifecta GT bioprostheses.

Authors:  Lise Tchouta; Daniel Liesman; Karen Kim; Shinichi Fukuhara
Journal:  JTCVS Tech       Date:  2020-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.